Trial reportThe journal of headache and pain2026
Effects of erenumab on migraine aura frequency: a REFORM study.
Trial report in The journal of headache and pain, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04603976 (Registry for Migraine - Clinical Core), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Registry for Migraine - Clinical Core
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-calcitonin gene-related peptide (CGRP) monoclonal antibodies effectively prevent migraine headache, but their impact on aura is unclear. The aim of this study was to characterize longitudinal changes in migraine aura frequency during and after preventive treatment with erenumab in adults with frequent, prospectively confirmed migraine aura.
methodsThis prospective, longitudinal, single-center investigation enrolled adults diagnosed with migraine with aura who reported ≥ 4 monthly migraine days and ≥ 2 monthly aura days during a 4-week baseline period. Erenumab was administered subcutaneously at a dose of 140 mg every 4 weeks for 24 weeks, followed by a 12-week post-treatment follow-up period. Headache and aura outcomes were recorded prospectively using standardized headache diaries completed throughout baseline, treatment, and follow-up. The primary outcome consisted of the mean absolute change in monthly aura days from baseline, evaluated at four-week intervals across the study period.
resultsEighty participants with migraine with aura provided outcome data eligible for analysis. The mean (SD) age was 43.1 (11.9) years, and 74 participants (93%) were female. At baseline, participants reported a mean of 8.0 (SD, 5.1) monthly aura days. After 24 weeks of treatment, the mean change in monthly aura days was - 4.9 (95% CI, - 5.8 to - 4.0) compared to baseline (p < 0.001). This improvement was partially sustained during the subsequent 12-week post-treatment follow-up, with a mean change of - 3.2 days (95% CI, - 4.2 to - 2.2) relative to baseline (p < 0.001). Exploratory analyses identified that greater reductions in monthly aura days were independently associated with a higher baseline number of monthly aura days (β = -0.60; 95% CI, - 0.72 to - 0.47; p < 0.001) and a greater reduction in monthly migraine days (β = -0.36; 95% CI, - 0.49 to - 0.23; p < 0.001).
conclusionsPreventive treatment with erenumab was associated with substantial and sustained reductions in aura frequency in adults with frequent migraine aura. These findings underscore the relevance of incorporating aura-specific outcomes into future controlled trials evaluating preventive migraine treatments.
trial registrationThe study was registered on ClinicalTrials.gov (NCT04603976).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.